EnviroGold Global: Unlocking America's Critical Metals
On July 23, 2025, the U.S. Department of the Interior issued Order No. 3436 titled ' Unlocking Critical and Strategic Minerals from Mine Waste '. The Order implements key provisions of the United States bipartisan national security and energy independence strategy and provides for the following:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
MediPharm Labs holds unique US Food and Drug Administration (FDA) site registration in relation to the manufacturing and release of pharmaceutical cannabis products. MediPharm is the only US FDA Audited purpose-built commercial cannabis facility in Canada. One of a handful globally. The possible rescheduling of cannabis in the US opens new opportunities for MediPharm in categories where the Company maintains a competitive advantage. TORONTO, Aug. 13, 2025 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to share insights on its US FDA site registration in relation to the possible rescheduling of cannabis in the United States. Communication from the US Federal Government and various media reports have indicated that the administration is reviewing the rescheduling of cannabis federally in the US. Speculation is that this will mean changing the classification of cannabis from a Schedule I drug to a Schedule III drug. What rescheduling means for cannabis in the United States: The rescheduling would recognize the medical benefits of cannabis at a federal level. Schedule III registration would drastically expand the possibility for US based research on medical cannabis products. Current, Schedule I drug classification puts controls in place that make it difficult for this research to be funded and undertaken today. This would open up the possibility for the US to expand special access medical cannabis programs, like those in Canada, Australia and Germany. How MediPharm is best positioned in the event of rescheduling cannabis in the US: MediPharm has gone through the complex process of a foreign drug manufacturing site registration with the US FDA. Following a week-long inspection by an FDA representative MediPharm was granted the ability to produce, label, test and release drugs. MediPharm has filed a drug master file (DMF) with the US FDA for CBD active pharmaceutical ingredient (API). The active ingredient file is required for drug manufacturers to source CBD for late-stage clinical trials and finished dose products. MediPharm has already shipped medical cannabis API and cannabis products to the US for research, including a National Institutes of Health (NIH) funded clinical trial. This delivery required the US FDA site registration and import permits issued by the US DEA. Upon possible rescheduling of cannabis, MediPharm Labs holds existing licences and expertise to serve the anticipated expansion of US based research and possible new medical special access programs. To MediPharm's understanding no other publicly listed cannabis-focused company in North America has this stack of licensing, including an FDA inspected cannabis facility. It takes years of regulatory and quality activities to achieve this suite of licensing, and enable clinical research with pharmaceutical cannabis. MediPharm Labs continues to maintain their top tier pharmaceutical licenses and registrations to continue its position as a leader in the global cannabis market. The Company will continue to monitor changes in the US scheduling of cannabis to serve researchers and patients with quality cannabis API and products. About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial scale domestic Good Manufacturing License for the extraction of multiple natural cannabinoids. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. In 2023, MediPharm acquired VIVO Cannabis Inc. which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical PTY and Beacon Medical GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions. Cautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, possible rescheduling of cannabis in the United States, the expansion of US based research on medical cannabis products, the expansion of special access medical cannabis programs in the US, opportunities for future clinical research opportunities, future marketable pharmaceutical products, and future Canadian and international commercial products that leverage MediPharm's unique pharmaceutical expertise. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; MediPharm's competitive licensing and FDA site inspection and registration; and other factors discussed in MediPharm Labs' filings, available on the SEDAR+ website at There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
Cision Canada
an hour ago
- Cision Canada
Argentina Lithium Enters into Amendment to Amelia Option Agreement
TSX Venture Exchange (TSX-V): LIT Frankfurt Stock Exchange (FSE): OAY3 OTCQB Venture Market: LILIF VANCOUVER, BC, Aug. 13, 2025 /CNW/ - Argentina Lithium & Energy Corp. (TSXV: LIT) (FSE: OAY3) (OTCQB: LILIF), ("Argentina Lithium" or the"Company") is pleased to announce that it has entered into an amendment (the " Fourth Addendum") to a previously announced option agreement (the " Amelia Option Agreement"). The Fourth Addendum sets the value of the Option Shares (as defined below) to be issued pursuant to the Amelia Option Agreement. On March 31, 2022, Argentina Litio Y Energia S.A., a wholly owned subsidiary of the Company (" ALE"), entered into the Amelia Option Agreement with an individual optionor (the " Amelia Optionor"). The Amelia Option Agreement grants ALE the option (the " Amelia Option") to acquire a 100% interest in three granted mine concession properties totaling 5,411 hectares in the Salar de Antofalla in Catamarca Province, Argentina (the " Amelia Properties"). On March 10, 2025, the parties amended the Amelia Option Agreement (the " Third Addendum") to modify the payment and investment schedule under the agreement. To exercise the Amelia Option, ALE must make the following cash payments to the Amelia Optionor: US$400,000 by December 31, 2025, US$500,000 by June 30, 2026, US$600,000 by December 31, 2026, and US$620,000 by June 30, 2027. In addition, ALE must invest US$2,000,000 in the Amelia Properties during the calendar year 2026 and US$4,000,000 during the calendar year 2027. Pursuant to the Fourth Addendum, the Company must also issue the equivalent number of Company shares (the " Option Shares") having a value of US$100,000 to the Amelia Optionor at a price of $0.06 per share using the Bank of Canada exchange rate of $1.4376 (CAD/USD) as at March 31, 2025, being the date of the Third Addendum. The issuance of the Option Shares is subject to the approval of the TSX-V. About Argentina Lithium Argentina Lithium & Energy Corp is focused on acquiring high quality lithium projects in Argentina and advancing them towards production in order to meet the growing global demand from the battery sector. The Company's strategic investment by Peugeot Citroen Argentina S.A., a subsidiary of Stellantis N.V., one of the world's leading automakers, places Argentina Lithium in a unique position to explore, develop and advance its four key projects covering over 70,000 hectares in the Lithium Triangle of Argentina. Management has a long history of success in the resource sector of Argentina and has assembled some of the most prospective lithium properties in the world renowned "Lithium Triangle". The Company is a member of the Grosso Group, a resource management group that has pioneered exploration in Argentina since 1993. ON BEHALF OF THE BOARD "Nikolaos Cacos" _______________________________ Nikolaos Cacos, President, CEO and Director Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains certain statements and information that may be considered "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements and forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved" and other similar expressions. In addition, statements in this news release that are not historical facts are forward looking statements, including, without limitation, the Company's expectation that it will meet the requirements of the TSX Venture Exchange necessary to issue shares pursuant to the Amelia Option Agreement, the Company's ability to make the future cash payments and investments required under the Amelia Option Agreement and the Company's business strategy, plans and outlooks. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include: the risk that the necessary regulatory approvals will not be obtained, including the approval of the Exchange; risks associated with the business of the Company; business and economic conditions in the mining industry generally; and other risk factors as detailed from time to time in the Company's continuous disclosure documents filed with Canadian securities regulators. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. We advise U.S. investors that the SEC's mining guidelines strictly prohibit information of this type in documents filed with the SEC. U.S. investors are cautioned that mineral deposits on adjacent properties are not indicative of mineral deposits on our properties. SOURCE Argentina Lithium & Energy Corp.
Cision Canada
an hour ago
- Cision Canada
Cascadia and Granite Creek Complete Business Combination
VANCOUVER, BC, Aug. 13, 2025 /CNW/ - Cascadia Minerals Ltd. (" Cascadia") (TSXV: CAM) (OTCQB: CAMNF) and Granite Creek Copper Ltd. (" Granite Creek") (TSXV: GCX) (OTCQB: GCXXF) are pleased to announce the acquisition by Cascadia of all of the issued and outstanding common shares of Granite Creek (the " Granite Creek Shares") pursuant to a court-approved plan of arrangement under the Business Corporations Act (British Columbia) (the " Arrangement"). The Arrangement, which became effective as of today's date, merges Granite Creek into Cascadia to create a leading Yukon copper-gold exploration and development company. Graham Downs, President and CEO of Cascadia, commented: "We are very excited to complete this merger, and we welcome Granite Creek Shareholders to Cascadia. The combined property portfolio provides our shareholders with exposure to an advanced-stage copper-gold deposit at the Carmacks Property and a compelling collection of discovery-stage copper-gold and epithermal gold projects throughout Yukon's underexplored Stikine Terrane. Planning is well underway for a fully-funded fall drill program at Carmacks that will focus on step-out drilling near high-grade portions of the deposit. In the meantime, crews are conducting prospecting work at our Macks, Milner, Idaho Creek and Rosy properties while we await results from our spring drilling at Catch". Upon completion of the Arrangement, each Granite Creek shareholder received 0.25 (the " Exchange Ratio") of a Cascadia common share (each whole share, a " Cascadia Share") in exchange for each previously held Granite Creek Share, with Cascadia issuing a total of 53,070,848 million Cascadia Shares to former Granite Creek shareholders. Pursuant to the transaction, previously outstanding stock options of Granite Creek have been exchanged for 3,747,500 stock options of Cascadia, and warrants to acquire Granite Creek Shares have been adjusted to permit their holders to acquire a total of 11,036,291 Cascadia Shares, in each case by applying the Exchange Ratio to the number and exercise prices of such options and warrants. Board of Directors of the Combined Company Timothy Johnston, Granite Creek's former President and CEO has joined Cascadia's board of directors. James Sabala and Kurt Allen have resigned from Cascadia's board of directors. Cascadia would like to thank Mr. Sabala and Mr. Allen for their valuable contributions, and wish them well in their future endeavours. Subscription Receipt Financing Further to the private placement announced in Cascadia's June 9, 2025, news release and closed on July 3, 2025, a total of 14,459,894 subscription receipts have been converted into Cascadia Shares and warrants (" Warrants"), and gross proceeds of C$2,024,385 have been released to Cascadia. The Cascadia Shares and Warrants issued in relation to the subscription receipts are not subject to a resale hold period in Canada. Each Warrant will entitle the holder thereof to purchase an additional Cascadia Share at a price of $0.24 per share until August 13, 2027. Cascadia has agreed to pay cash finders' fees totaling $82,223 and issued a total of 587,308 finder warrants (" Finder Warrants") to finders comprising Castlewood Capital Corp., Consultant Financier Integritas Inc., Ventum Financial Corp., and BT Global Growth Inc. in connection with the subscription receipt financing. The finders are each at arm's length to Cascadia. Each Finder Warrant shall be exercisable on the same terms as the Warrants. The payment of these finder's fees is subject to receipt of TSXV approval. Additional Information about the Arrangement Further information regarding the Arrangement is set out in the news releases of Cascadia and Granite Creek dated June 9, 2025 and which has been publicly filed by Cascadia and Granite Creek under their respective profiles on SEDAR+ at and the management information circular of Granite Creek dated July 4, 2025 (the " Circular") which has been publicly filed under Granite Creek's profile on SEDAR+ at About Cascadia Cascadia's flagship asset is the Carmacks Project in the high-grade Minto copper district in Yukon Territory, Canada. The project is located south of and within 35km of the past-producing Minto mine, which was recently acquired by Selkirk Copper Mines. The Carmacks Project hosts a Measured and Indicated Resource containing 651 Mlbs of copper and 302 koz of gold (36.3 million tonnes grading 0.81 % copper, 0.26 g/t gold, and 3.23 g/t silver and 0.01% molybdenum) with a 2023 PEA demonstrating positive economic potential ($230.5 M Post-Tax NPV (5%) and 29% Post-Tax IRR). Cascadia also has a pipeline of discovery stage copper-gold properties throughout the Yukon Stikine Terrane including its Catch Property, which hosts a copper-gold porphyry discovery where inaugural drill results returned broad intervals of mineralization (116.60 m of 0.31% copper with 0.30 g/t gold). Catch exhibits extensive high-grade copper and gold mineralization across a 5 km long trend, with rock samples returning peak values of 3.88% copper, 1,065 g/t gold, and 267 g/t silver. QA/QC The technical information in this news release has been approved by Andrew Carne, VP Corporate Development for Cascadia and a qualified person for the purposes of National Instrument 43-101. Prospecting grab samples referenced in this release represent highlight results only, and include results from 2024 and previous seasons. Below detection values for copper, gold and silver have been encountered in grab samples in these target areas. For more details on Catch drilling and prospecting results, please see Cascadia's News Releases dated July 25, 2024, and July 19, 2023. The Mineral Resources and economic analysis disclosed here are referenced from the 2023 Technical Report on the Carmacks Project Preliminary Economic Assessment, authored by SGS Canada Inc. for Granite Creek Copper. Pricing for the Carmacks Project PEA base case economic analysis was US $3.75/lb copper, US $1,800/oz gold, and US $22/oz silver at an exchange rate of $1:US$0.75. The results of the Carmacks preliminary economic assessment are preliminary in nature, it includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves, and there is no certainty that the preliminary economic assessment will be realized. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. Cautionary note regarding forward-looking statements: This press release may contain "forward-looking information" within the meaning of applicable securities laws. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this press release. Cascadia and Granite Creek undertake no obligation to update forward-looking information, except as required by securities laws.
